Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Novartis Pharmaceuticals

37 clinical trials · 37 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Novartis Pharmaceuticals

RECRUITINGNCT05703516

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

This is an open label, prospective, multicenter, non-comparative study to assess the safety and effectiveness of Tabrecta® (Capmatinib) in real world setting. Also, this study is...

Sponsor: Novartis PharmaceuticalsEnrolling: 25012 locations
Non-Small-Cell Lung Carcinoma
RECRUITINGNCT06514521

Post Marketing Study on Pluvicto in Korea

Post marketing study on Pluvicto in Korea

Sponsor: Novartis PharmaceuticalsEnrolling: 2788 locations
Metastatic Castration-resistant Prostate Cancer
RECRUITINGPhase 3NCT04094311

Study of Out of Specification for Tisagenlecleucel

This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of...

Sponsor: Novartis PharmaceuticalsEnrolling: 20020 locations
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell Lymphoma
RECRUITINGPhase 2NCT06004661

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With...

This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of...

Sponsor: Novartis PharmaceuticalsEnrolling: 209 locations
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RECRUITINGPhase 1NCT07261631

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309...

Sponsor: Novartis PharmaceuticalsEnrolling: 1805 locations
Pancreatic Ductal AdenocarcinomaNon-Small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast Cancer+3
RECRUITINGPhase 1 / Phase 2NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients...

Sponsor: Novartis PharmaceuticalsEnrolling: 27520 locations
Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5
RECRUITINGPhase 2NCT07094516

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD...

Sponsor: Novartis PharmaceuticalsEnrolling: 40720 locations
Alzheimer's Disease
RECRUITINGPhase 4NCT06733922

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of...

Sponsor: Novartis PharmaceuticalsEnrolling: 22414 locations
Relapsing Remitting Multiple Sclerosis (RRMS)
RECRUITINGPhase 3NCT07326709

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease...

Sponsor: Novartis PharmaceuticalsEnrolling: 7702 locations
Huntington Disease
RECRUITINGPhase 2NCT05646381

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of...

The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the...

Sponsor: Novartis PharmaceuticalsEnrolling: 50220 locations
Aortic Stenosis
RECRUITINGPhase 3NCT06597019

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to \<12 years) with heterozygous familial...

Sponsor: Novartis PharmaceuticalsEnrolling: 5120 locations
Familial Hypercholesterolemia - Heterozygous
RECRUITINGPhase 1 / Phase 2NCT07048197

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis...

A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease

Sponsor: Novartis PharmaceuticalsEnrolling: 2711 locations
Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
RECRUITINGPhase 3NCT05126277

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With...

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination...

Sponsor: Novartis PharmaceuticalsEnrolling: 46220 locations
Lupus Nephritis
RECRUITINGPhase 2NCT05268289

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Sponsor: Novartis PharmaceuticalsEnrolling: 24020 locations
Lupus Nephritis
RECRUITINGPhase 3NCT06133972

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus...

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the...

Sponsor: Novartis PharmaceuticalsEnrolling: 55020 locations
Systemic Lupus Erythematosus
RECRUITINGNCT06382051

Modifying PEST for Psoriatic Arthritis Screening

The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with...

Sponsor: Novartis PharmaceuticalsEnrolling: 50215 locations
Plaque PsoriasisPsoriatic Arthritis
RECRUITINGNCT07243782

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With...

Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea

Sponsor: Novartis PharmaceuticalsEnrolling: 761 location
Hidradenitis SuppurativaPediatric Plaque PsoriasisJuvenile Idiopathic Arthritis
RECRUITINGPhase 2NCT06470048

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to...

Sponsor: Novartis PharmaceuticalsEnrolling: 20020 locations
Diffuse Cutaneous Systemic Sclerosis
RECRUITINGPhase 3NCT06744920

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With...

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care...

Sponsor: Novartis PharmaceuticalsEnrolling: 18020 locations
Generalized Myasthenia Gravis
RECRUITINGPhase 3NCT06517758

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants...

The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG...

Sponsor: Novartis PharmaceuticalsEnrolling: 14620 locations
Generalized Myasthenia Gravis
RECRUITINGPhase 1 / Phase 2NCT06704269

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a...

Sponsor: Novartis PharmaceuticalsEnrolling: 1510 locations
Generalized Myasthenia Gravis
RECRUITINGPhase 2NCT06868290

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis...

Sponsor: Novartis PharmaceuticalsEnrolling: 12620 locations
ANCA Associated Vasculitis (AAV)
RECRUITINGPhase 1 / Phase 2NCT06910813

DFT383 in Pediatric Participants With Nephropathic Cystinosis

An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a...

Sponsor: Novartis PharmaceuticalsEnrolling: 304 locations
Nephropathic Cystinosis
RECRUITINGPhase 2NCT07235046

A Study of DII235 in Adults With Elevated Lipoprotein(a)

The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).

Sponsor: Novartis PharmaceuticalsEnrolling: 20020 locations
Lipoprotein Disorder
RECRUITINGPhase 3NCT06597006

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial...

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous familial...

Sponsor: Novartis PharmaceuticalsEnrolling: 918 locations
Familial Hypercholesterolemia - Homozygous
RECRUITINGPhase 4NCT06501443

LATAM LOWERS LDL-C

This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on...

Sponsor: Novartis PharmaceuticalsEnrolling: 52011 locations
Hypercholesterolaemia
RECRUITINGPhase 2NCT05222529

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12...

The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared...

Sponsor: Novartis PharmaceuticalsEnrolling: 4220 locations
Asthma
RECRUITINGPhase 3NCT05562466

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in...

The purpose of this study is to evaluate the superiority in terms of efficacy and evaluate the safety of QMF149 (indacaterol (acetate) / mometasone (furoate)) compared to...

Sponsor: Novartis PharmaceuticalsEnrolling: 20020 locations
Asthma
RECRUITINGPhase 2NCT06665256

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory...

Sponsor: Novartis PharmaceuticalsEnrolling: 12320 locations
Idiopathic Inflammatory Myopathies
RECRUITINGPhase 2NCT05750628

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium...

Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria

Sponsor: Novartis PharmaceuticalsEnrolling: 32712 locations
Uncomplicated Plasmodium Falciparum Malaria

Showing 30 of 37 trials.